January 2017 in “Journal of Investigative Dermatology Symposium Proceedings” The 2015 Hair Research Congress concluded that stem cells, maraviroc, and simvastatin could potentially treat Alopecia Areata, topical minoxidil, finasteride, and steroids could treat Frontal Fibrosing Alopecia, and PTGDR2 antagonists could also treat alopecia. They also found that low-level light therapy could help with hair loss, a robotic device could assist in hair extraction, and nutrition could aid hair growth. They suggested that Alopecia Areata is an inflammatory disorder, not a single disease, indicating a need for personalized treatments.
October 2023 in “Biomaterials” Nanotechnology could improve hair regrowth but faces challenges like complexity and safety concerns.
Peptide hydrogels show promise for healing skin, bone, and nerves but need improvement in stability and compatibility.
March 2023 in “Anais Brasileiros De Dermatologia” Topical minoxidil is the best-supported treatment for female hair loss, but personalized plans are needed.
March 2023 in “International Journal of Molecular Sciences” ADSC-Exos with miR-122-5p can help treat hair loss by promoting hair growth.
January 2023 in “Applied sciences” Equisetum debile extracts may help with skin whitening, anti-wrinkle, and anti-hair loss treatments.
December 2022 in “Molecular Pharmaceutics” Latanoprost-loaded nanotransfersomes could help treat hair loss by promoting hair growth.
May 2021 in “F1000Research” The treatment led to denser, thicker hair growth and less hair loss.
January 2012 in “Journal of the American Academy of Dermatology” 2011 dermatology discussions highlighted stem cell hair treatments, new lichen planopilaris therapies, skin side effects from cancer drugs, emerging allergens, and the link between food allergies and skin issues.
22 citations,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.